The most valuable therapeutic targets to study the phenomenon of chemoresistance in advanced ovarian cancer are proteins: kinase inhibitors, PARP inhibitors, and immune-checkpoint inhibitors. This evidence concerns the gene PARP1 and ovarian carcinoma.